Supply updates

Last updated 26 June 2019

We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.

Fluarix Tetra is now only available for government programs

The significant number of influenza notifications so early this season compared to other years has driven a significant increase in demand for GSK’s seasonal influenza vaccine, Fluarix Tetra. GSK has already released a large amount of its reserve doses into the private market, with this year being the largest private market allocation of doses compared to previous years.

GSK has received urgent requests from governments for additional doses, particularly for the vaccination of children under five years of age. Consequently, GSK has taken the decision to divert all of its remaining Fluarix Tetra vaccine doses to these important programs.

For clarity, all government program supplies of Fluarix Tetra are secure and have either been delivered, or are planned to be, in the next few weeks.

Customers should note that there are alternative seasonal influenza vaccines produced by other suppliers that may still be available for private market supply until notified otherwise.


Supply update for measles, mumps, rubella and varicella-containing vaccines

Priorix Tetra

GSK will experience a supply constraint of its measles, mumps, rubella & varicella (MMRV) combination vaccine, Priorix Tetra, from the beginning of May to the end of October 2019.

This shortage will impact our ability to supply Priorix Tetra to the National Immunisation Program (NIP) and to non-government customers. GSK has worked with the Commonwealth Department of Health to ensure that an alternative MMRV vaccine will be available during this time, ensuring no impact to children’s immunisations as part of the NIP.


GSK is also currently experiencing a supply constraint of its measles, mumps and rubella (MMR) combination vaccine, Priorix, for non-government customers until 1 October 2019 due to provision of vaccine to measles outbreak control programs in a number of states and territories. This constraint does not affect the supply of Priorix to the NIP.


Hepatitis-containing vaccines

GSK is experiencing supply constraints of the below hepatitis-containing vaccines. These supply constraints are due to manufacturing capacity and are not related to vaccine quality or safety.

  • Havrix Adult - inactivated hepatitis A virus vaccine
  • Havrix Junior - inactivated hepatitis A virus vaccine
  • Twinrix Adult - combined hepatitis A and hepatitis B vaccine
  • Twinrix Junior - combined hepatitis A and hepatitis B vaccine

Supply of GSK’s hepatitis-containing vaccines to Government programs are not impacted.

Please note, the following GSK hepatitis-containing vaccines continue to be in stock.

  • Engerix B Adult - hepatitis B surface antigen recombinant (yeast) vaccine
  • Engerix B Paediatric hepatitis B surface antigen recombinant (yeast) vaccine

We expect to provide the next update in July 2019.


Herpes zoster vaccine

GSK’s herpes zoster vaccine, Shingrix, is not available in Australia. There is currently no confirmed timing for the supply of Shingrix to Australia.


Ventolin (salbutamol sulfate) 5mg/2.5mL nebules

GSK is experiencing a supply constraint of its Ventolin 5mg nebules. This is due to high global demand for the product, with local demand also increasing due to an alternative brand of salbutamol inhalation ampoules being out of stock in Australia. We anticipate intermittent supply throughout 2019. 

This supply constraint does not affect other Ventolin products, including Ventolin Metered Dose Inhalers (also known as ‘puffers’) which continue to be in supply.


Please visit the TGA website for ongoing updates to supply.

For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.